Antimicrobial resistance poses a significant threat to public health globally and in Canada. Wide regional variability in antimicrobial resistance and ongoing increases in global travel present an important risk for the acquisition and transmission of drug-resistant organisms. Travel from high-income to low-and middle-income countries, particularly the Indian subcontinent, present the greatest risks for acquiring a drug-resistant Enterobacteriaceae. Risk factors for returning from travel with drug-resistant organisms include seeking medical care while abroad, travellers' diarrhea and antibiotic use. Health care professionals can play an important role in preventing harm for travellers by counselling patients on the risks of acquiring drug-resistant organisms, appropriate antibiotic prescribing for travellers' diarrhea and tailored empiric therapy for patients presenting with infection after travel.
Introduction
Antimicrobial resistance (AMR) is a growing problem globally. It is identified as one of the most significant public health threats of our time. In the absence of meaningful intervention, it is estimated that deaths from drug-resistant infections will increase from 700,000 to 10 million annually by 2050, surpassing current cancer rates as the number one cause of death (1) . Moreover, the prevalence of drug-resistant organisms across the globe varies widely. For example, resistance of Escherichia coli to third-generation cephalosporins is much more common in India, at 78%, than in Canada, at 9% (2) .
In this global society, AMR knows no borders. In 2017, the number of passengers using air travel exceeded four billion for the first time; this number is forecast to double by 2036 (3) .
One of the big challenges of AMR with respect to travel is infections from drug-resistant Enterobacteriaceae. Enterobacteriaceae are a large family of gram-negative bacilli that can cause a wide range of infections including those affecting the urinary, respiratory and gastrointestinal tracts. Organisms in this family include E. coli, Klebsiella species, Enterobacter species and Salmonella species. A key mechanism of Enterobacteriaceae antibiotic resistance is the development of beta-lactamase and carbapenemase enzymes, which hydrolyze beta-lactam antibiotics, rendering them ineffective. Genes for these enzymes are commonly encoded by plasmids, which can transfer between bacterial organisms. Key groups of Enterobacteriaceae resistance are extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE), and carbapenem-resistant Enterobacteriaceae (CRE). Of growing importance is the plasmid-mediated colistin-resistance gene mcr-1. The ability of bacteria to transfer antimicrobial resistant genes to one another via plasmids poses significant infection control challenges. A rise in Enterobacteriaceae resistance translates to more infection-related mortalities, longer hospital stays and increased costs to the health care system (4,5).
The objective of this article is to describe the clinically relevant risk of drug-resistant organisms associated with travel, with a focus on Enterobacteriaceae. For the purposes of this review, travel is defined as movement of people travelling to low-and middle-income countries in Asia, Africa and the Americas, and returning to high-income countries such as Australia, Canada, New Zealand, United States (US) and those in Europe.
OVERVIEW
What is the risk of bringing home drug-resistant bacteria after travel?
The studies on the risk of travellers acquiring either ESBL-PE or CRE are sobering and have important considerations to the management of patients in Canada.
Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE)
One of the largest studies to evaluate the risk of acquiring a drug-resistant organism during travel focused on the importation of ESBL-PE to the Netherlands. Through a longitudinal cohort study of 2001 travellers, the authors determined the likelihood of ESBL-PE colonization before and after the travel period. Of those individuals who did not have an ESBL-PE prior to travel, 34% acquired an ESBL-PE while abroad (6) . There was marked variability in the risk of ESBL-PE colonization associated with the region visited. Travel to southern Asia presented the highest risk, at 75% incidence of colonization, followed by central and eastern Asia (49%), western Asia (43%), southeastern Asia (37%), the Caribbean and Central America (28%), middle and eastern Africa (28%), western Africa (19%), South America (18%) and southern Africa (6%). The median duration of colonization after travel was 30 days (95% confidence interval [CI]: 29-33 days). However, 11.3% remained colonized after 12 months, highlighting the importance of identifying an individual's travel history within the previous year. Multiple other smaller studies have also evaluated the risk of ESBL-PE acquisition while travelling (7). The average risk of ESBL-PE colonization after travel is 643 per 1,000 travellers from the Indian subcontinent, 340 per 1,000 travellers from Africa and 186 per 1,000 travellers from Central and South America ( Figure 1 ). Although the majority of studies focus on the risk of colonization with drug-resistant organisms, recent travel has been associated with an increased risk of ESBL-PE urinary tract infections (8-11) and bacteremia with ESBL-PE post-transrectal prostate biopsy (12) .
Carbapenem-resistant Enterobacteriacae (CRE)
CRE infections, which have also been increasing around the world, are of particular concern due to the limited treatment options and the high infection-related mortality rates of 40% to 70% (13, 14) . The three main classes of carbapenemase-producing Enterobacteriaceae that confer carbapenem resistance have distinct regional epidemiology (15) The Canadian Nosocomial Infection Surveillance Program (CNISP) recently characterized carbapenemase-producing Enterobacteriaceae reported in hospitals across Canada from 2010 to 2014. The incidence was 0.07 cases per 1,000 admissions, with KPC and NDM-1 being the most common. Many of those affected had a history of international travel. India was the most common travel destination with 31% of cases reporting travel to that country within the previous 12 months (17). However, the risk of acquiring a CRE while travelling is considerably lower than the risk of acquiring an ESBL-PE (Figure 1 ).
Colistin-resistance gene, mcr-1
Of further concern is the recently described plasmid-mediated colistin resistance gene mcr-1 which can be co-located with other gram-negative resistance mechanisms. Colistin is one of few antibiotic options for managing CRE; however, it carries significant risk of nephrotoxicity and neurotoxicity. Initially discovered in animal and human clinical isolates in China, mcr-1 has now been reported in clinical isolates globally (18) . A recent Dutch study found that 5% of long-distance travellers had mcr-1 in fecal samples. These travellers had primarily visited southeast Asia or southern Africa (19) .
Travel is also playing a role in the spread of other drug-resistant bacterial organisms such as Salmonella, Shigella and Campylobacter species, which has been reviewed elsewhere (7) .
What are the risk factors for acquiring drug-resistant organisms while travelling?
Health care exposure
Recent health care exposure abroad has been noted as a risk factor for acquiring a drug-resistant organism. In the CNISP evaluation of Canadian patients with CRE, of those with a travel history available, 86% had sought medical care abroad (17) . The association between health care exposure while travelling and drug-resistant organisms has also been observed in a number of European studies (20) (21) (22) (23) (24) (25) (26) (27) 
Travellers' diarrhea
Travellers' diarrhea is caused by ingesting contaminated food or beverages containing bacterial enteropathogens (32) . Depending on the travel location and host factors, the incidence of diarrhea during travel can range from 10% to 40%. In several studies of travellers acquiring drug-resistant organisms abroad, travellers' diarrhea was noted as a significant risk factor, particularly for acquiring an ESBL-PE. Travellers' diarrhea is associated with an approximate 2-to 3-fold increased risk of acquiring an ESBL-PE abroad (6, 33, 34) . In a study of Finnish travellers, this risk of acquiring an ESBL-PE was 11% in those without travellers' diarrhea, 21% in those with travellers' diarrhea who did not take antibiotics and 37% in those with travellers' diarrhea who were treated with antibiotics (33).
Antibiotic exposure
Antibiotics apply selective pressure to the native organisms colonizing the gut, increasing the risk that drug-resistant organisms contracted abroad are incorporated into the microbiome. Treatment with antibiotics has been repeatedly demonstrated to present a risk to travellers. In the previously mentioned Dutch study of travellers who acquired ESBL-PEs abroad, antibiotic use was associated with a greater than 2-fold risk of acquiring these drug-resistant organisms (OR=2.7; 95% CI: 1.8-4.0) (6). In a Finnish study, 21% of those who received no treatment, 20% of those treated with the anti-diarrheal medication loperamide alone, 40% of those treated with antibiotics alone and 71% of those treated with both loperamide and antibiotics became colonized with ESBL-PE (35).
Among travellers hospitalized abroad, the risk associated with antibiotic treatment was also pronounced, with an 11-fold higher risk of being colonized with an MDRO (OR=10.7; 95% CI: 4.2-27.3) compared to those who did not travel abroad; however, being hospitalized abroad and not receiving an antibiotic was not a risk factor for MDRO colonization in this study (26) . The importance of antibiotic exposure during a travel-associated hospitalization is echoed in a large study in Finland, where risk of colonization with an MDRO was significantly increased in those receiving antibiotics (OR=3.2; OVERVIEW 95% CI: 2.3-4.5) (23) . Similarly, a study in the Netherlands found a 2.5-to 3.4-fold increased risk of gram-positive MDRO colonization in those who had been treated with antibiotics while hospitalized abroad (20) .
What can clinicians do to minimize harm in Canadian travellers?
By understanding the risk of AMR associated with travel, health care professionals will be better able to implement approaches to improve management and reduce transmission of drug-resistant organisms as well as educate the public to make informed decisions ( Figure 2) . Opportunities for clinicians include:
• Counselling patients, pretravel, on the risk of acquiring a drug-resistant organism, tailored to the patient's itinerary and specific region of travel ( Figure 1 ) • Counselling patients on the risks of unplanned health care exposure abroad; minimizing the risk through pretravel immunizations and counselling on how to prevent travellers' diarrhea and avoid high risk activities • Counselling patients on the risks of medical tourism, tailored to the patient's itinerary and specific region of travel ( Figure 1 
Post travel
Counsel patients about the risks of acquiring a drug-resistant organism tailored to their itinerary and region of travel 
